Medicare is considering covering the weight-loss treatment drug Wegovy, popular among celebrities, but only for those with a history of heart disease using it to prevent heart attacks and strokes. This move could expand access, especially since current Medicare plans do not cover obesity treatments. The drug, semaglutide, helps reduce appetite and cardiovascular risk, but its high cost may decrease as more competitors enter the market. Negotiations on pricing under President Biden’s Inflation Reduction Act could make Wegovy more accessible to those in need.

Oviva Therapeutics, a pharma company, aims to develop a drug allowing women to delay or potentially prevent menopause. Founder Daisy Robinton expressed optimism despite the treatment being in early stages. The drug, using anti-Müllerian hormone, targets ovarian rejuvenation. With previous success in animal trials, the innovation presents a unique approach to managing menopause. This bold vision offers women the possibility of extended health span and optional menopause through therapeutic intervention, challenging traditional views on aging and reproductive health.

A new study from China, published in the science journal Andrology, reveals a concerning link between prolonged computer use for leisure and the increased risk of erectile dysfunction. Researchers found that for every 1.2 hours per day spent on a computer, men raised their chances of experiencing erectile dysfunction by 3.57 times. While moderate physical activity could potentially help alleviate this issue, further research is needed to confirm these findings and their implications for men’s health.

Scientists have made strides in using CRISPR gene editing to potentially eliminate HIV by cutting out “bad” DNA from infected cells, with hopes of developing a cure strategy, as reported by the BBC. While early findings show promise in targeting dormant HIV in cell samples, challenges remain in proving the effectiveness and safety of this approach in treating the virus on a larger scale in animals and humans.

After nearly a decade of endorsing Weight Watchers, Oprah Winfrey has shifted gears, questioning the CEO of her former sponsor, now known as WW International, during an ABC special. Winfrey challenged the necessity of WeightWatchers in light of drugs like Zepbound and Wegovy. Sistani, WW’s current CEO, defended the program, emphasizing community and education. Winfrey’s departure from the board caused a stock drop, highlighting the struggle to adapt to changing attitudes towards weight and health.